An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC
-
Published:2024-06
Issue:
Volume:153
Page:106814
-
ISSN:1368-8375
-
Container-title:Oral Oncology
-
language:en
-
Short-container-title:Oral Oncology
Author:
Wang HuiORCID,
Hu Liyang,
Zhang Fenghua,
Fang Min,
Xu Jianping,
Li Min,
Chen Zebin
Reference39 articles.
1. Head and neck cancer;Mody;Lancet,2021
2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
3. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016
4. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019
5. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma;Saâda-Bouzid;Ann Oncol,2017